Elevance Health, Inc. (ELV) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELV SEC filings page.
Elevance Health, Inc. (ELV) reported $201.1B in revenue over the twelve months to Jun 30, 2026, up 6.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has expanded, but thinner margins, weaker cash conversion, and rising leverage make growth more resource-intensive.
Since FY2021, net profit margin has fallen to2.8% and free cash flow margin to1.6% . That paired compression means each dollar of revenue is yielding less accounting profit and less cash available after reinvestment.
By FY2025, operating margin was
Debt-to-equity reached 0.7x in FY2025, up from 0.6x in FY2021, while interest expense reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Elevance Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Elevance Health, Inc. has an operating margin of 3.6%, meaning the company retains $4 of operating profit per $100 of revenue. This results in a moderate score of 58/100, indicating healthy but not exceptional operating efficiency. This is down from 4.4% the prior year.
Elevance Health, Inc.'s revenue grew 12.5% year-over-year to $199.1B, a solid pace of expansion. This earns a growth score of 59/100.
Elevance Health, Inc. has elevated debt relative to equity (D/E of 0.70), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 26/100, reflecting increased financial risk.
Elevance Health, Inc.'s current ratio of 1.54 indicates adequate short-term liquidity, earning a score of 43/100. The company can meet its near-term obligations, though with limited headroom.
Elevance Health, Inc. has a free cash flow margin of 1.6%, earning a moderate score of 34/100. The company generates positive cash flow after capital investments, but with room for improvement.
Elevance Health, Inc. earns a strong 12.9% return on equity (ROE), meaning it generates $13 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100. This is down from 14.5% the prior year.
Elevance Health, Inc. scores 3.15, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Elevance Health, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Elevance Health, Inc. generates $0.76 in operating cash flow ($4.3B OCF vs $5.7B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Elevance Health, Inc. earns $5.13 in operating income for every $1 of interest expense ($7.2B vs $1.4B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Elevance Health, Inc. generated $50.5B in revenue in Q2 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.
Elevance Health, Inc.'s EBITDA was $2.1B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 24.1% from the same quarter a year earlier. Against the prior quarter it is down 12.7%.
Elevance Health, Inc. reported $1.5B in net income in Q2 2026. This represents a decrease of 16.1% from the same quarter a year earlier. Against the prior quarter it is down 17.1%.
Elevance Health, Inc. earned $6.71 per diluted share (EPS) in Q2 2026. This represents a decrease of 13.1% from the same quarter a year earlier. Against the prior quarter it is down 16.1%.
Cash & Balance Sheet
Elevance Health, Inc. generated $1.6B in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 9.0% from the same quarter a year earlier. Against the prior quarter it is down 60.3%.
Elevance Health, Inc. held $10.2B in cash against $30.7B in long-term debt as of Q2 2026.
Elevance Health, Inc. paid $1.72 per share in dividends in Q2 2026. This represents an increase of 0.6% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Elevance Health, Inc.'s operating margin was 3.5% in Q2 2026, reflecting core business profitability. This is down 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.
Elevance Health, Inc.'s net profit margin was 2.9% in Q2 2026, showing the share of revenue converted to profit. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Elevance Health, Inc.'s ROE was 3.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
Not reported for Q2 2026.
Capital Allocation
Elevance Health, Inc. spent $234.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 38.1% from the same quarter a year earlier. Against the prior quarter it is down 79.2%.
Elevance Health, Inc. invested $287.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 22.1%.
Not reported for Q2 2026.
ELV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.5B+1.4% | $50.2B+2.6% | $49.7B+9.5% | $50.7B+12.4% | $49.8B+13.4% | $48.9B+14.8% | $45.4B+6.6% | $45.1B+5.3% |
| Cost of Revenue | $5.5B+3.8% | $5.5B+9.6% | $5.5B-8.2% | $5.4B+5.6% | $5.3B+9.8% | $5.0B+30.3% | $6.0B+24.3% | $5.1B+9.6% |
| SG&A Expenses | $5.5B+11.0% | $6.3B+19.4% | $5.4B+12.7% | $5.3B+0.1% | $5.0B-1.4% | $5.3B+8.5% | $4.8B-3.9% | $5.3B-3.7% |
| Operating Income | $1.8B-27.3% | $2.1B-34.2% | $309.0M-54.1% | $1.3B-8.0% | $2.4B-12.3% | $3.2B+5.1% | $673.0M-47.6% | $1.4B-19.8% |
| EBITDA | $2.1B-24.1% | $2.4B-31.1% | $715.0M-52.5% | $1.7B+2.6% | $2.8B+1.4% | $3.5B+5.9% | $1.5B-35.9% | $1.6B-17.1% |
| Interest Expense | $364.0M+6.7% | $357.0M+3.8% | $366.0M+7.6% | $351.0M+17.0% | $341.0M+21.8% | $344.0M+29.8% | $340.0M+31.3% | $300.0M+15.8% |
| Income Tax | $483.0M-11.9% | $544.0M-11.3% | -$331.0M-271.5% | $219.0M-40.0% | $548.0M-20.0% | $613.0M-11.2% | $193.0M+13.5% | $365.0M+3.1% |
| Net Income | $1.5B-16.1% | $1.8B-19.2% | $547.0M+30.9% | $1.2B+17.0% | $1.7B-24.2% | $2.2B-2.8% | $418.0M-51.2% | $1.0B-21.2% |
| EPS (Basic) | $6.74-12.9% | $8.03-16.7% | $2.55+36.4% | $5.32+21.5% | $7.74-21.9% | $9.64-0.1% | $1.87-49.2% | $4.38-20.1% |
| EPS (Diluted) | $6.71-13.1% | $8.00-16.8% | $2.54+35.8% | $5.32+22.0% | $7.72-21.6% | $9.61+0.2% | $1.87-48.9% | $4.36-20.0% |
| Diluted Shares (Avg) | 218M-3.5% | 220M-3.0% | N/A | 224M-4.0% | 226M-3.3% | 227M-3.0% | N/A | 233M-1.4% |
Not reported in any period shown, so not listed: Gross Profit, R&D Expenses.
ELV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $126.4B+3.7% | $125.8B+5.1% | $121.5B+3.9% | $122.7B+5.3% | $121.9B+7.9% | $119.7B+7.0% | $116.9B+7.3% | $116.5B+5.5% |
| Current Assets | $67.2B+6.1% | $67.0B+9.7% | $63.0B+6.9% | $63.8B+1.5% | $63.3B+1.7% | $61.1B+0.3% | $58.9B-1.8% | $62.8B+2.7% |
| Cash & Equivalents | $10.2B+19.5% | $9.7B+28.8% | $9.5B+14.5% | $8.7B+10.8% | $8.6B+31.8% | $7.5B+20.5% | $8.3B+27.0% | $7.9B-28.0% |
| Short-Term Investments | $25.7B+1.7% | $25.9B+1.8% | $25.9B+2.7% | $26.3B-9.2% | $25.3B-12.5% | $25.4B-13.9% | $25.2B-14.9% | $29.0B+4.1% |
| Long-Term Investments | $1.3B+15.8% | $1.1B+5.1% | $1.1B+8.3% | $1.1B+24.4% | $1.1B+28.0% | $1.1B+20.5% | $1.0B+18.2% | $893.0M+9.4% |
| Goodwill | $28.3B-0.1% | $28.3B-0.3% | $28.3B+0.2% | $28.5B+9.6% | $28.4B+9.3% | $28.4B+9.5% | $28.3B+11.7% | $26.0B+2.7% |
| Total Liabilities | $81.4B+4.3% | $81.8B+6.1% | $77.5B+2.7% | $78.7B+8.3% | $78.1B+10.5% | $77.1B+8.3% | $75.5B+8.5% | $72.7B+1.0% |
| Current Liabilities | $44.3B+1.0% | $45.3B+6.1% | $41.0B+1.1% | $40.9B-2.7% | $43.8B+4.8% | $42.7B-3.7% | $40.6B-2.9% | $42.0B-3.0% |
| Non-Current Liabilities | $37.2B+8.5% | $36.5B+6.0% | $36.4B+4.4% | $37.8B+23.4% | $34.3B+18.6% | $34.4B+28.1% | $34.9B+25.8% | $30.6B+7.1% |
| Long-Term Debt | $30.7B+8.8% | $30.8B+9.5% | $30.8B+5.4% | $31.2B+26.3% | $28.2B+14.7% | $28.1B+27.9% | $29.2B+25.7% | $24.7B+2.7% |
| Total Equity | $44.9B+2.7% | $43.9B+3.3% | $43.9B+6.2% | $44.0B+0.4% | $43.7B+3.6% | $42.5B+4.7% | $41.3B+5.1% | $43.8B+13.9% |
| Retained Earnings | $36.7B+3.2% | $35.8B+3.6% | $35.4B+5.5% | $35.6B+1.2% | $35.5B+2.8% | $34.5B+4.4% | $33.5B+5.7% | $35.2B+9.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
ELV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.9B-6.9% | $4.3B+326.0% | $84.0M-88.1% | $1.1B-57.6% | $2.1B+359.5% | $1.0B-48.6% | $706.0M+123.8% | $2.7B+2.4% |
| Depreciation & Amortization | $366.0M-3.7% | $354.0M-5.1% | $406.0M+2.0% | $387.0M+67.5% | $380.0M | $373.0M+12.7% | $398.0M-62.6% | $231.0M+5.0% |
| Stock-Based Compensation | N/A | $55.0M-32.1% | N/A | N/A | N/A | $81.0M+30.6% | N/A | N/A |
| Capital Expenditures | $287.0M+7.5% | $235.0M+19.9% | $293.0M-9.0% | $360.0M+8.4% | $267.0M-17.3% | $196.0M-29.7% | $322.0M-1.2% | $332.0M+4.1% |
| Free Cash Flow | $1.6B-9.0% | $4.1B+399.0% | -$209.0M-154.4% | $775.0M-67.0% | $1.8B+1341.1% | $821.0M-51.7% | $384.0M+111.6% | $2.3B+2.2% |
| Investing Cash Flow | $159.0M+123.1% | -$1.6B-1694.2% | $464.0M+128.3% | -$1.2B-205.2% | -$687.0M+16.0% | $103.0M+104.5% | -$1.6B-59.2% | -$401.0M+41.6% |
| Financing Cash Flow | -$1.5B-385.1% | -$2.5B-31.7% | $236.0M-83.2% | $243.0M+126.6% | -$308.0M-146.1% | -$1.9B-6065.6% | $1.4B+457.4% | -$915.0M+7.9% |
| Dividends Paid | $373.0M-3.1% | $376.0M-2.6% | $377.0M+1.1% | $376.0M-2.6% | $385.0M+1.9% | $386.0M+1.8% | $373.0M+7.8% | $386.0M+10.9% |
| Share Buybacks | $234.0M-38.1% | $1.1B+27.7% | $471.0M-74.0% | $876.0M+1360.0% | $378.0M-18.4% | $880.0M+55.5% | $1.8B+95.2% | $60.0M-87.5% |
ELV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3.5%-1.4pp | 4.2%-2.3pp | 0.6%-0.9pp | 2.5%-0.6pp | 4.9%-1.4pp | 6.5%-0.6pp | 1.5%-1.5pp | 3.1%-1.0pp |
| Net Margin | 2.9%-0.6pp | 3.5%-0.9pp | 1.1%+0.2pp | 2.3%+0.1pp | 3.5%-1.7pp | 4.5%-0.8pp | 0.9%-1.1pp | 2.3%-0.8pp |
| Return on Equity | 3.3%-0.7pp | 4.0%-1.1pp | 1.3%+0.2pp | 2.7%+0.4pp | 4.0%-1.5pp | 5.1%-0.4pp | 1.0%-1.2pp | 2.3%-1.0pp |
| Return on Assets | 1.2%-0.3pp | 1.4%-0.4pp | 0.4%+0.1pp | 1.0%+0.1pp | 1.4%-0.6pp | 1.8%-0.2pp | 0.4%-0.4pp | 0.9%-0.3pp |
| Current Ratio | 1.52+0.1x | 1.480.0x | 1.54+0.1x | 1.56+0.1x | 1.440.0x | 1.43+0.1x | 1.450.0x | 1.50+0.1x |
| Debt-to-Equity | 0.680.0x | 0.700.0x | 0.700.0x | 0.71+0.1x | 0.64+0.1x | 0.66+0.1x | 0.71+0.1x | 0.56-0.1x |
| Asset Turnover | 0.400.0x | 0.400.0x | 0.410.0x | 0.410.0x | 0.410.0x | 0.410.0x | 0.390.0x | 0.390.0x |
| FCF Margin | 3.2%-0.4pp | 8.2%+6.5pp | -0.4%-1.3pp | 1.5%-3.7pp | 3.6%+3.3pp | 1.7%-2.3pp | 0.9%+8.6pp | 5.2%-0.2pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Elevance Health, Inc. ELV | FY2025 | $199.1B | $5.7B | 2.8% | $89.5B | 49/100 |
| The Cigna Group CI | FY2025 | $274.9B | $6.0B | 2.2% | $74.3B | 42/100 |
| CVS Health Corporation CVS | FY2025 | $402.1B | $1.8B | 0.4% | $112.3B | 35/100 |
| Humana Inc. HUM | FY2025 | $129.7B | $1.2B | 0.9% | $46.5B | 50/100 |
| Centene Corporation CNC | FY2025 | $194.8B | -$6.7B | -3.4% | $31.9B | 36/100 |
| Molina Healthcare, Inc. MOH | FY2025 | $45.4B | $472.0M | 1.0% | $10.2B | 63/100 |
Where Elevance Health, Inc. Ranks
Frequently Asked Questions
What is Elevance Health, Inc.'s annual revenue?
Elevance Health, Inc. (ELV) reported $199.1B in total revenue for fiscal year 2025. This represents a 12.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Elevance Health, Inc.'s revenue growing?
Elevance Health, Inc. (ELV) revenue grew by 12.5% year-over-year, from $177.0B to $199.1B in fiscal year 2025.
Is Elevance Health, Inc. profitable?
Yes, Elevance Health, Inc. (ELV) reported a net income of $5.7B in fiscal year 2025, with a net profit margin of 2.8%.
What is Elevance Health, Inc.'s EBITDA?
Elevance Health, Inc. (ELV) had EBITDA of $8.7B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Elevance Health, Inc. have?
As of fiscal year 2025, Elevance Health, Inc. (ELV) had $9.5B in cash and equivalents against $30.8B in long-term debt.
What is Elevance Health, Inc.'s operating margin?
Elevance Health, Inc. (ELV) had an operating margin of 3.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Elevance Health, Inc.'s net profit margin?
Elevance Health, Inc. (ELV) had a net profit margin of 2.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Elevance Health, Inc.'s return on equity (ROE)?
Elevance Health, Inc. (ELV) has a return on equity of 12.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Elevance Health, Inc.'s free cash flow?
Elevance Health, Inc. (ELV) generated $3.2B in free cash flow during fiscal year 2025. This represents a -30.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Elevance Health, Inc.'s operating cash flow?
Elevance Health, Inc. (ELV) generated $4.3B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Elevance Health, Inc.'s total assets?
Elevance Health, Inc. (ELV) had $121.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Elevance Health, Inc.'s capital expenditures?
Elevance Health, Inc. (ELV) invested $1.1B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Elevance Health, Inc.'s current ratio?
Elevance Health, Inc. (ELV) had a current ratio of 1.54 as of fiscal year 2025, which is generally considered healthy.
What is Elevance Health, Inc.'s debt-to-equity ratio?
Elevance Health, Inc. (ELV) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Elevance Health, Inc.'s return on assets (ROA)?
Elevance Health, Inc. (ELV) had a return on assets of 4.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Elevance Health, Inc.'s P/E ratio?
Elevance Health, Inc. (ELV) trades at 18.0x earnings, its market capitalization divided by net income of $5.0B net income, trailing 12 months to June 30, 2026. The market capitalization is $89.5B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Elevance Health, Inc.'s price-to-sales ratio?
Elevance Health, Inc. (ELV) trades at 0.4x sales, its market capitalization divided by revenue of $201.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $89.5B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Elevance Health, Inc.'s Altman Z-Score?
Elevance Health, Inc. (ELV) has an Altman Z-Score of 3.15, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Elevance Health, Inc.'s Piotroski F-Score?
Elevance Health, Inc. (ELV) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Elevance Health, Inc.'s earnings high quality?
Elevance Health, Inc. (ELV) has an earnings quality ratio of 0.76x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Elevance Health, Inc. cover its interest payments?
Elevance Health, Inc. (ELV) has an interest coverage ratio of 5.13x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Elevance Health, Inc.?
Elevance Health, Inc. (ELV) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.